Novaferon in Non-hospitalized Adult Patients With Mild COVID-19
Phase 3
- Conditions
- Covid19
- Interventions
- Biological: NovaferonBiological: Placebo
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Genova Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT05172037
- Locations
- 🇯🇵
Tokyo Shinagawa Hospital, Tokyo, Japan
Novaferon for COVID-19 Treatment Trial (NCTT-005)
Phase 3
- Conditions
- Covid19
- Interventions
- Biological: NovaferonBiological: Placebo
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Genova Inc.
- Target Recruit Count
- 385
- Registration Number
- NCT04708158
- Locations
- 🇯🇵
Omi Medical Center, Shiga, Japan
🇯🇵Kamagaya General Hospital, Chiba, Japan
🇯🇵Chiba Aoba Municipal Hospital, Chiba, Japan
Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19
Phase 3
- Conditions
- Covid19
- Interventions
- Biological: NovaferonBiological: Placebo
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Genova Inc.
- Target Recruit Count
- 914
- Registration Number
- NCT04669015
- Locations
- 🇧🇷
Hospital Felício Rocho, Horizonte, Brazil
🇧🇷Hospital 9 de Julho, São Paulo, Brazil
🇧🇷Instituto de Moléstias Cardiovalsculares Tatuí Ltda, Tatuí, Brazil
© Copyright 2025. All Rights Reserved by MedPath